GCG and metabolic dysfunction-associated steatohepatitis: Other weight loss agents, including GLP-1 RA/gastric inhibitory polypeptide (e.g., tirzepatide) analogs and GLP-1 RA/glucagon agonists (e.g., cotadutide), are also undergoing clinical trials to assess their effects on NASH (107, 108).